AKER - Akers Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4600
+0.0250 (+5.75%)
At close: 3:40PM EDT
Stock chart is not supported by your current browser
Previous Close0.4350
Open0.4450
Bid0.4305 x 800
Ask0.4600 x 1200
Day's Range0.4424 - 0.4725
52 Week Range0.4000 - 3.9200
Volume255,129
Avg. Volume180,937
Market Cap5.756M
Beta (3Y Monthly)-1.55
PE Ratio (TTM)N/A
EPS (TTM)-0.7150
Earnings DateNov 13, 2019 - Nov 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.86
Trade prices are not sourced from all markets
  • GlobeNewswire

    Akers Biosciences Reports Q2 2019 Earnings

    Akers Biosciences, Inc. (AKER) (“Akers Bio” or the “Company”), a developer of rapid health information technologies, reported its financial results for the three and six months ended June 30, 2019. At June 30, 2019, Akers Bio had cash, restricted cash and marketable securities of $4.39 million. The Board of Directors’ process remains underway to evaluate strategic alternatives to maximize shareholder value.

  • Local companies impacted by trade war-fueled stock market decline
    American City Business Journals

    Local companies impacted by trade war-fueled stock market decline

    Among the Philadelphia region’s largest 20 publicly traded companies, three in the chemical industry experienced the biggest dips in midday trading.

  • GlobeNewswire

    The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Akers Biosciences, Inc. Common Stock -- AKER

    NEWARK, N.J., July 29, 2019 -- The Rosen Law Firm, P.A. announces that the United States District Court District of New Jersey has approved the following announcement of a.

  • Markit

    See what the IHS Markit Score report has to say about Akers Biosciences Inc.

    Akers Biosciences Inc NASDAQ:AKERView full report here! Summary * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for AKER with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $450 million over the last one-month into ETFs that hold AKER are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire

    Akers Biosciences Reports Q1 2019 Earnings

    Akers Biosciences, Inc. (AKER) (“Akers Bio” or the “Company”), a developer of rapid health information technologies, reported its financial results for the three months ended March 31, 2019. At March 31, 2019, Akers Bio had cash, restricted cash and marketable securities of $5.23 million. During the fourth quarter of 2018, the Board of Directors initiated a process to evaluate strategic alternatives to maximize shareholder value.

  • As losses mount, medical device maker continues pursuit of 'strategic alternatives'
    American City Business Journals

    As losses mount, medical device maker continues pursuit of 'strategic alternatives'

    South Jersey medical device maker Akers Biosciences Inc. — which saw its sales cut in half last year — said it is continuing to evaluate 'strategic alternatives" that include looking at business combinations in alternative sectors such as cannabis related industries. “Our focus throughout the latter part of 2018 and into 2019 has been on streamlining the company’s operations, rightsizing human resources with a concentration on products which currently generate sales, cutting unnecessary corporate expense and resolving legacy issues," said Howard R. Yeaton, CEO and interim-CFO at Akers BioSciences (NASDAQ: AKER).

  • GlobeNewswire

    Akers Biosciences Reports Fiscal Year 2018 Earnings

    Akers Biosciences, Inc. (AKER) (“Akers Bio” or the “Company”), a developer of rapid health information technologies, reported its financial results for the fiscal year ended December 31, 2018. At December 31, 2018, Akers Bio had cash, restricted cash and marketable securities of $5.96 million, which the Company reports is sufficient to fund its obligations into 2020. The process is ongoing and will consider a range of potential strategic alternatives including, but not limited to, business combinations in alternative sectors including cannabis related industries.

  • GlobeNewswire

    Factors of Influence in 2019, Key Indicators and Opportunity within ARRIS International plc, Edwards Lifesciences, DENTSPLY SIRONA, Vail Resorts, Akers Biosciences, and DURECT — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE

    4 Healthcare Stocks That Are Raising Eyebrows

    CORAL GABLES, FL / ACCESSWIRE / December 31, 2018 / With the new year only a few short moments away, the healthcare sector is electrified with excitement given that industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. Premier Health Group (PHGRF) (PHGI), Akers Biosciences Inc (AKER), vTv Therapeutics Inc (VTVT), and Achillion Pharmaceuticals, Inc (ACHN) represent 4 healthcare stocks to watch on Monday. Premier Health Group (PHGRF) (PHGI) is a company that is dead-set on investing in the development of innovative, high tech treatment solutions for patients in the primary care space.

  • ACCESSWIRE

    These 4 Healthcare Stocks Are Heating Up

    CORAL GABLES, FL / ACCESSWIRE / December 28, 2018 / The healthcare industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. From data-based approaches and analysis consumer demands/needs, advancements in the sector may catalyze potential opportunities for those looking to healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Akers Biosciences Inc (AKER), CASI Pharmaceuticals Inc (CASI), and Rite Aid Corporation (RAD) represent 4 healthcare companies innovating towards the future. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced, earlier this month that as part of its overarching strategy to cover major verticals associated with primary care, it had signed into a binding Letter of Intent (LOI) agreement to acquire a Vancouver-based pharmacy.

  • GlobeNewswire

    Market Trends Toward New Normal in Gartner, CONVERGEONE HLD, Syros Pharmaceuticals, Akers Biosciences, Edge Therapeutics, and Cracker Barrel Old Country Store — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Benzinga

    This Tiny Biotech Firm Is Weighing An Entrance Into Cannabis

    Akers Biosciences, Inc. (NASDAQ: AKER)'s stock was trending on Benzinga Pro Tuesday, with shares of the microcap trading on 40-percent higher than average volume. The stock's decline — it was down 11.7 percent at $1.54 at the time of publication Tuesday — follows the 42.28-percent jump the shares registered Monday following an announcement that the company could enter the cannabis industry. What Is Akers? Akers Biosciences develops and manufactures rapid screening and testing products for health care providers and consumers.

  • ACCESSWIRE

    Today’s Research Reports on Stocks to Watch: Akers Biosciences and Align Technology

    NEW YORK, NY / ACCESSWIRE / November 20, 2018 / While Akers Biosciences shares were exploding on the news that the company is considering the cannabis industry, shares of Align Technology were plummeting on a pessimistic highlight of the company in the Wall Street Journal from over the weekend. Align Technology, Inc. Akers Biosciences, Inc. shares closed up 42.28% on Monday on tremendous trading volume of nearly 15.4 million shares traded.

  • South Jersey medical device firm exploring cannabis industry combination
    American City Business Journals

    South Jersey medical device firm exploring cannabis industry combination

    The Thorofare, N.J., company which began exploring "strategic alternatives" earlier this month has hired a legal advisor to advise it on potential business combinations in the cannabis industry.

  • Apple shares down after cutting production orders for all three iphone models
    Yahoo Finance Video

    Apple shares down after cutting production orders for all three iphone models

    Yahoo Finance's Julie Hyman highlights todays stocks on the move in midday trading.